Affymetrix Launches 3' IVT Express Kit for Faster, More Reliable Target Preparation
September 03 2008 - 8:00AM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) today announced the launch of its 3�
IVT Express Kit, a faster and more reliable option for manual
target preparation on Affymetrix� industry-standard 3� IVT array
cartridges. The kit offers new streamlined protocols and requires
less starting sample material, enabling researchers to generate
high-quality gene expression results faster than before. Using less
starting material is of benefit to cancer researchers because
samples are precious. The 3� IVT Express Kit requires only 50 ng
per sample, which is up to up to 20 times less than the previous
One Cycle Kit. The other key benefit is that assays can be run in
just one day with 500 ng of starting material input versus two days
with the One Cycle Kit. This allows assays to be completed
overnight. �As a core lab about two-thirds of the sample sizes we
receive are small, so the decreased input required by Affymetrix�
new kit is a huge advantage,� said Daniel Tessier, senior director,
Operations and Business Development, McGill University and G�nome
Qu�bec Innovation Centre. �We have been testing the 3� IVT Express
Kit and we have found that it has radically sped up our ability to
process samples and deliver high-quality results for researchers
across Canada and beyond.� �Affymetrix has set the standard in the
industry for whole-genome 3� expression arrays with thousands of
peer-reviewed publications citing the technology,� said Kevin King,
president of Affymetrix. �The more affordable 3� IVT Express Kit
simplifies the workflow process for our customers and enables them
to make discoveries and publish results faster than before. The
smaller sample requirements should open the door to new research
that will increase our ability to understand how genes are
expressed in complex diseases, especially relating to cancer.� For
more information on the Affymetrix 3� IVT Express Kit, please
visit: http://www.affymetrix.com/genechip/ivtexpress.affx. About
Affymetrix Affymetrix GeneChip� microarray technology is the
industry-standard tool for analyzing complex genetic information.
After inventing microarray technology in the late 1980s, Affymetrix
scientists have been dedicated to developing innovative products
that provide researchers with a more complete view of the genome.
These products continue to accelerate genetic research and enable
scientists to develop diagnostics and tailor treatments for
individual patients by identifying and measuring the genetic
information associated with complex diseases. Today, Affymetrix
technology is used by the world�s top pharmaceutical, diagnostic
and biotechnology companies, as well as leading academic,
government and not-for-profit research institutes. More than 1,700
systems have been shipped around the world and more than 13,000
peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Sacramento, Calif., Cleveland, Ohio,
and Singapore. The company has about 1,100 employees worldwide and
maintains sales and distribution operations across Europe and Asia.
For more information about Affymetrix, please visit the company�s
website at www.affymetrix.com. About G�nome Qu�bec G�nome Qu�bec is
a private non-profit organization whose mission is to reinforce
Qu�bec�s innovation system in genomics by financing major genomics
research initiatives. Investments of more than $400 million since
2001 have contributed to accelerate the discovery of new
applications such as screening tests, therapeutic tools in human
health or new environmental procedures in agriculture and forestry.
The funds invested by G�nome Qu�bec come from the minist�re du
D�veloppement �conomique, de l�Innovation et de l�Exportation of
Qu�bec, the Government of Canada through Genome Canada and from
private partners. To find out more about G�nome Qu�bec and
genomics, visit its Web site at www.genomequebec.com.
Forward-looking Statements All statements in this press release
that are not historical are �forward-looking statements� within the
meaning of Section 21E of the Securities Exchange Act as amended,
including statements regarding Affymetrix� �expectations,�
�beliefs,� �hopes,� �intentions,� �strategies� or the like. Such
statements are subject to risks and uncertainties that could cause
actual results to differ materially for Affymetrix from those
projected, including, but not limited to: risks and uncertainties
relating to commercial success of the Affymetrix 3� IVT Express Kit
discussed in this press release; risks of the company�s ability to
achieve and sustain higher levels of revenue, higher gross margins
and reduced operating expenses; uncertainties related to
technological approaches, manufacturing and product development;
personnel retention; uncertainties related to cost and pricing of
Affymetrix products; dependence on collaborative partners;
uncertainties related to sole-source suppliers; risks associated
with past and future acquisitions; uncertainties relating to FDA
and other regulatory approvals; competition; risks relating to
intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are
discussed in Affymetrix� Form 10-K for the year ended December 31,
2007, and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix� expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. NOTE: Affymetrix, the
Affymetrix logo and GeneChip� are registered trademarks owned or
used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2023 to Aug 2024